Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Mehmet Asim Bilen"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In this review, we aim to provide a comprehensive assessment of the evolving landscape of the perioperative management in renal cell carcinoma (RCC), emphasizing its dynamic and intricate nature. We explore academic and clinical insights into the per
Externí odkaz:
https://doaj.org/article/f69fa3ef76bc489793bc0fd865c1b941
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Emilie Elise Hitron, Greta Anne Russler, Lauren Yantorni, Sarah Caulfield, Jacqueline T. Brown, Jamie M. Goldman, Bassel Nazha, Bradley C. Carthon, Wayne B. Harris, Omer Kucuk, Viraj A Master, Mehmet Asim Bilen
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 52-57 (2022)
Introduction: There are three combination immune checkpoint inhibitor (ICI)–based regimens in the first-line setting for metastatic renal cell carcinoma (mRCC). Currently, there is limited real-world data for clinical outcomes and toxicity in mRCC
Externí odkaz:
https://doaj.org/article/3b523ccfbd2e4ae9ba07ac843f39a4e8
Autor:
Alexandra Medline, Eric Midenberg, Dattatraya Patil, Sean Evans, Nikhil Vettikattu, Fatima Kamal, Kenneth Ogan, Sarah P. Psutka, Mehmet Asim Bilen, Viraj A. Master
Publikováno v:
JCSM Rapid Communications, Vol 5, Iss 2, Pp 205-211 (2022)
Abstract Background Preoperative skeletal muscle deficiency is an established risk factor for poor survival outcomes in patients with renal cell carcinoma (RCC). However, given the dynamic nature of skeletal muscle associated with malignancy, there i
Externí odkaz:
https://doaj.org/article/5801308526a844d2b837cb3880bb9e49
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/6454908bfd214dbaa717e2bb9b3bf6cf
Autor:
Tony Zibo Zhuang, Lara Harik, Seth Force, Agreen Hadadi, Mehmet Asim Bilen, Jacqueline T. Brown, Bradley C. Carthon, Jamie Goldman, Omer Kucuk, Viraj A. Master, Bassel Nazha
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received
Externí odkaz:
https://doaj.org/article/82d35e8cfd2f4bd2a107b982a151d13f
Autor:
T. Anders Olsen, Dylan J. Martini, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Bassel Nazha, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between Afr
Externí odkaz:
https://doaj.org/article/3aa9b41eb0064fb78cd9cab2b089a0c5
Autor:
Dylan J. Martini, Meredith R. Kline, Yuan Liu, Julie M. Shabto, Bradley C. Carthon, Greta Anne Russler, Lauren Yantorni, Emilie Elise Hitron, Sarah Caulfield, Jamie M. Goldman, Wayne B. Harris, Omer Kucuk, Viraj A Master, Mehmet Asim Bilen
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100393- (2021)
Background: Cabozantinib is an effective treatment for metastatic renal cell carcinoma (mRCC). The international mRCC database consortium (IMDC) criteria is the gold standard for risk stratification in mRCC. We created a risk scoring system specific
Externí odkaz:
https://doaj.org/article/88cfc89656924a159ed5e19c6f52d91b
Autor:
Greta Russler, Bassel Nazha, Sarah Caulfield, Mehmet Asim Bilen, Yuan Liu, Bradley C. Carthon, Sean Evans, Wayne Harris, Omer Kucuk, Jacqueline T. Brown, Viraj A. Master, Jamie M. Goldman, Dylan J. Martini, Lauren Yantorni, Ogul E. Uner, T. Anders Olsen, Julie M. Shabto
Publikováno v:
Clin Genitourin Cancer
Background : Full dose cabozantinib for metastatic renal cell carcinoma (mRCC) is 60mg, but adverse events (AEs) may require dose reductions. Limited data exist comparing efficacy among cabozantinib doses. We compared AEs and clinical outcomes in mRC
Autor:
Paul B. Robbins, Elaine T. Lam, Mehmet Asim Bilen, James Larkin, Alessandra di Pietro, Aly-Khan A. Lalani, Lance C. Pagliaro, Toni K. Choueiri, John B. A. G. Haanen, Eric Voog, Bradley Alexander McGregor, Nikolay Kislov, Bo Huang, Laurence Albiges, Stan Krulewicz, Brian I. Rini, Martin H. Voss
Publikováno v:
Clinical Cancer Research. 28:738-747
Purpose: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. Experimental Design: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component,
Autor:
Dattatraya Patil, Vikram M. Narayan, Reza Nabavizadeh, Milton Williams, Dylan J. Martini, Kenneth Ogan, Shreyas S. Joshi, Sean Steele, Michelle I. Higgins, Viraj A. Master, Aarti Sekhar, Mehmet Asim Bilen, Sarah P. Psutka
Publikováno v:
Cancer. 127:1974-1983
Background Body composition and inflammation are gaining importance for prognostication in cancer. This study investigated the individual and combined utility of the preoperative skeletal muscle index (SMI) and the modified Glasgow Prognostic Score (